What it is: A five-amino-acid synthetic peptide that stimulates the pituitary gland to release growth hormone in natural pulses without meaningfully raising cortisol or prolactin.
Research suggests: Human studies confirm GH stimulation with a selective profile that avoids the cortisol and prolactin elevation seen with older compounds in the same class.
Best for: Growth hormone and sleep quality researchers
Key thing to know: Frequently studied in combination with CJC-1295, which works through a complementary pathway to produce additive GH effects.
What is Ipamorelin?
Ipamorelin is a synthetic pentapeptide , a chain of five amino acids , that belongs to a class of compounds called growth hormone secretagogues (GHS). Unlike synthetic growth hormone itself, ipamorelin does not introduce external GH into the body. Instead, it stimulates the pituitary gland to release the body's own growth hormone in a pulsatile pattern that more closely resembles natural GH secretion rhythms.
Researchers have studied ipamorelin for its potential role in body composition improvement, recovery enhancement, sleep quality, and the broader effects of optimized growth hormone levels , including its impact on IGF-1 production in the liver. It is notable among GH secretagogues for its selectivity profile, which is consistently highlighted in the research literature.
How it works.
Ipamorelin works by binding to the ghrelin receptor , also called the growth hormone secretagogue receptor (GHS-R) , located primarily in the pituitary gland. Activation of this receptor triggers a pulse of growth hormone release. GH then travels to the liver and other tissues, where it stimulates the production of IGF-1 (insulin-like growth factor 1), which mediates many of GH's downstream effects on muscle, fat metabolism, and cellular repair.
What distinguishes ipamorelin from older GH secretagogues like GHRP-2 and GHRP-6 is its selectivity. Research indicates it produces GH pulses without meaningfully elevating cortisol or prolactin , two hormones that older compounds in this class were known to stimulate. Think of it as a precise knock on the pituitary's door that says "release GH now" , without triggering the broader stress hormone cascade.
Ipamorelin is frequently studied in combination with CJC-1295, a GHRH analogue that works through a different but complementary pathway. Together, research suggests they produce both a sustained elevation of baseline GH and a discrete pulsatile release , an approach studied for additive effects on GH activity.
What the research shows.
Human studies on ipamorelin confirm it produces meaningful growth hormone pulses with a favorable selectivity profile. Its ability to stimulate GH release without significantly elevating cortisol or prolactin has been demonstrated in clinical pharmacology studies, distinguishing it from less selective compounds in the GHS class.
However, large long-term randomized controlled trials examining clinical outcomes in general healthy populations are limited. Much of the human research focuses on specific populations , older adults, post-surgical recovery, or short-term pharmacokinetic studies. The long-term safety and efficacy data that exists for FDA-approved GH therapies has not been replicated for ipamorelin at the same scale.
The evidence is sufficient to establish the mechanism and acute GH response, but insufficient to make strong claims about long-term outcomes. Research that does exist is generally consistent with the mechanistic model. This is Moderate evidence , human data exists confirming the primary mechanism, but large outcome-focused trials are limited.
Biomarkers to review first.
Research protocols for ipamorelin typically reference the following biomarkers as baseline context. Testing these before exploring this peptide gives you and your healthcare provider the most relevant starting information.
What it's commonly researched with.
Ipamorelin is most frequently studied in combination with GHRH analogues, where the two compounds act on complementary pathways to produce additive effects on GH output. The combinations below reflect what appears in the research literature , not recommendations for use without clinical supervision.